IMPROVE Bleeding Risk Score

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • No Increased Risk0–6.9
  • Increased Risk7–30.5
Direct Clinical Answer

The IMPROVE Bleeding Risk Score calculates assessing bleeding risk at hospital admission for acutely ill medical patients, particularly when considering anticoagulation therapy. Key inputs include age category. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Assesses bleeding risk at hospital admission for acutely ill medical patients, particularly when considering anticoagulation therapy. The IMPROVE Bleeding Risk Score was developed from an international observational database of 15,156 patients across 52 hospitals in 12 countries to predict major bleeding and clinically relevant non-major bleeding within 14 days of admission. The cumulative incidence of major and non-major but clinically relevant in-hospital bleeding within 14 days of admission was 3.2%. This validated tool helps clinicians identify patients at high risk for bleeding complications and assess the risk-benefit ratio of pharmacological thromboprophylaxis. Patients with scores ≥7 have significantly greater rates of major bleeding (3.9% vs 1.2%) and should be carefully evaluated before anticoagulation.

Clinical Indication

The IMPROVE Bleeding Risk Score is indicated for bedside clinical practice to support Assesses bleeding risk at hospital admission for acutely ill medical patients, particularly when considering anticoagulation therapy. The IMPROVE Bleeding Risk Score was developed from an international observational database of 15,156 patients across 52 hospitals in 12 countries to predict major bleeding and clinically relevant non-major bleeding within 14 days of admission. The cumulative incidence of major and non-major but clinically relevant in-hospital bleeding within 14 days of admission was 3.2%. This validated tool helps clinicians identify patients at high risk for bleeding complications and assess the risk-benefit ratio of pharmacological thromboprophylaxis. Patients with scores ≥7 have significantly greater rates of major bleeding (3.9% vs 1.2%) and should be carefully evaluated before anticoagulation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Enhanced bleeding monitoring recommended for high-risk patients requiring anticoagulation.

Formula & Variables:

Score = Age points (0, 1.5, or 3.5) + Male gender (1) + Renal function points (0, 1, or 2.5) + Cancer (2) + Rheumatic disease (2) + Central venous catheter (2) + ICU/CCU (2.5) + Hepatic failure (2.5) + Platelet <50k (4) + Recent bleeding (4) + Active GI ulcer (4.5)

Input Parameters

NameTypeRequiredDescription
age_categorystringYesPatient age category. Age is a significant predictor of bleeding risk, with risk increasing progressively with advanced age due to physiological changes, comorbidities, and polypharmacy
genderstringYesPatient gender. Male gender is associated with increased bleeding risk in hospitalized patients, possibly due to higher rates of cardiovascular disease and antiplatelet therapy use
renal_functionstringYesGlomerular filtration rate (GFR) category. Reduced renal function increases bleeding risk through impaired drug clearance, uremic bleeding tendency, and altered platelet function
current_cancerstringYesActive cancer within 6 months prior to admission. Cancer increases bleeding risk through tumor-related factors, chemotherapy effects, thrombocytopenia, and invasive procedures
rheumatic_diseasestringYesPresence of rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, other autoimmune conditions). Associated with increased bleeding risk due to disease-related factors and immunosuppressive medications
central_venous_catheterstringYesPresence of central venous catheter. Central lines increase bleeding risk through direct vascular access, procedural complications, and potential for catheter-related bleeding
icu_ccu_staystringYesCurrent stay in intensive care unit (ICU) or coronary care unit (CCU). Critical care setting indicates severe illness with increased bleeding risk from procedures, medications, and hemodynamic instability
hepatic_failurestringYesHepatic failure defined as INR >1.5. Liver dysfunction significantly increases bleeding risk through reduced synthesis of coagulation factors and impaired hemostasis
platelet_count_categorystringYesPlatelet count category. Thrombocytopenia (<50,000/μL) significantly increases bleeding risk through impaired primary hemostasis and platelet plug formation
bleeding_in_3_monthsstringYesHistory of bleeding in the 3 months prior to admission. Recent bleeding history is a strong predictor of recurrent bleeding events and indicates underlying bleeding tendency
active_gastroduodenal_ulcerstringYesPresence of active gastroduodenal ulcer. Active peptic ulcer disease represents the highest bleeding risk factor due to ongoing mucosal erosion and potential for life-threatening hemorrhage

Score Interpretation & Guidance

RangeStageDescription
0–6.9No Increased RiskScore <7 points
7–30.5Increased RiskScore ≥7 points

Evidence-Based References (EBM)

  • Spyropoulos AC, Anderson FA Jr, FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-714. doi: 10.1378/chest.10-1944.DOI: 10.1378/chest.10-1944
  • Hostler DC, Marx ES, Moores LK, et al. Validation of the International Medical Prevention Registry on Venous Thromboembolism bleeding risk model. Chest. 2016 Apr;149(4):1002-1009. doi: 10.1378/chest.15-2082.DOI: 10.1378/chest.15-2082
  • Rosenberg D, Eichorn A, Alarcon M, et al. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014 Nov 4;3(6):e001152. doi: 10.1161/JAHA.114.001152.DOI: 10.1161/JAHA.114.001152
  • Stuck AK, Spirk D, Schaudt J, Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review. Thromb Haemost. 2017 May 3;117(5):801-808. doi: 10.1160/TH16-08-0631.DOI: 10.1160/TH16-08-0631

Related calculators